Breaking News Instant updates and real-time market news.

TXMD

TherapeuticsMD

$5.97

0.03 (0.51%)

09:51
12/01/16
12/01
09:51
12/01/16
09:51

TherapeuticsMD uniquely positioned for 'clean label' for Yuvvexy, says Jefferies

Jefferies analyst Matthew Andrews noted that the Congressional Caucus for Women's Issues has urged the FDA to reconsider labeling of low-dose vaginal estrogen therapy for vulvovaginal atrophy and that the FDA is "clearly committed" to potentially amend their labels. A label without the warnings would be a "game-changer" for TherapeuticsMD's Yuvvexy, expanding its market to 32M women from 8M, and the drug is uniquely positioned to potentially be the first to receive such a "clean label," said Andrews, who keeps a Buy rating on the stock.

TXMD TherapeuticsMD
$5.97

0.03 (0.51%)

11/29/16
GUGG
11/29/16
NO CHANGE
GUGG
TherapeuticsMD selloff a buying opportunity, says Guggenheim
Guggenheim analyst Louise Chen believes weakness in TherapeuticsMD is a compelling buying opportunity. Chen said the weakness appears to be driven by a short presentation which sounds like a "rehash" of a prior short thesis published on the blog site "SeekingAlpha.com" with little new information. The analyst expects positive data for TX-001HR in 4Q16, and potential approval for Yuvvexy on its PDUFA date of 5/7/17, both of which she believes have blockbuster potential. Chen has a Buy rating on TherapeuticsMD shares.
11/30/16
STFL
11/30/16
NO CHANGE
STFL
TherapeuticsMD Phase III trial likely to be successful, says Stifel
Stifel analyst Annabel Samimy expects the Phase III trial of TherapeuticsMD's estradiol+progesterone for the treatment of vasomotor symptoms in menopausal women to show that the three highest doses of the company's drug are "efficacious." The analyst says that estradiol has successfully reduced VMS symptoms in prior trials. She keeps a $14 price target and a Buy rating on the shares.
11/30/16
JEFF
11/30/16
NO CHANGE
Target $18
JEFF
Buy
TherapeuticsMD short thesis a 'hodgepodge' that ignores '001, says Jefferies
Jefferies analyst Matthew Andrews attributes yesterday's slide in TherapeuticsMD to a short thesis presented by an investor at the Robin Hood Conference, though he views the thesis as a "hodgepodge" of topics, many of which have already been expressed by bears. Andrews said nothing in the short call impacts his expectation for positive REPLENISH trial data and sales of Yuvvexy and TX-001HR. He keeps a Buy rating and $18 price target on TherapeuticsMD shares.
12/01/16
GSCO
12/01/16
NO CHANGE
GSCO
TherapeuticsMD recent weakness an attractive buying opportunity, say Goldman
Goldman analsyt Jami Rubin said pressure to remove the black box label for TherapeuticsMD's Yuvexxy is growing as indicated by a letter from members of Congress to the FDA on October 11. The analyst said it represents a growing movement to increase accessibility for low-dose estrogen products that pose limited systemic risk. Rubin views TherapeuticsMD's recent share weakness as an attractive buying opportunity ahead of 2017 catalysts and upcoming data from the Phase III RELENISH study. The analyst rates TherapeuticsMD a Buy with a $10.50 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.